ACASTI PHARMA INC (ACST) Stock Price & Overview
NASDAQ:ACST • CA00430K8656
The current stock price of ACST is 3.37 USD. Today ACST is down by -0.88%. In the past month the price increased by 8.01%. In the past year, price increased by 40.42%.
ACST Key Statistics
- Market Cap
- 34.172M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.04
- Dividend Yield
- N/A
ACST Stock Performance
ACST Stock Chart
ACST Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ACST. When comparing the yearly performance of all stocks, ACST is one of the better performing stocks in the market, outperforming 86.9% of all stocks.
ACST Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACST. ACST has a great financial health rating, but its profitability evaluates not so good.
ACST Earnings
ACST Forecast & Estimates
7 analysts have analysed ACST and the average price target is 8.16 USD. This implies a price increase of 142.14% is expected in the next year compared to the current price of 3.37.
ACST Groups
Sector & Classification
ACST Financial Highlights
Over the last trailing twelve months ACST reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 78.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.41% | ||
| ROE | -19.28% | ||
| Debt/Equity | 0 |
ACST Ownership
ACST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.65 | 944.634B | ||
| JNJ | JOHNSON & JOHNSON | 20.92 | 587.317B | ||
| MRK | MERCK & CO. INC. | 22.63 | 289.492B | ||
| PFE | PFIZER INC | 9.1 | 154.439B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 122.453B | ||
| ZTS | ZOETIS INC | 17.02 | 50.862B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.9 | 26.518B | ||
| VTRS | VIATRIS INC | 5.61 | 16.212B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.5 | 11.768B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.508B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.528B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.81B | ||
| LGND | LIGAND PHARMACEUTICALS | 25 | 4.233B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACST
Company Profile
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The company is headquartered in Laval, Quebec. The company went IPO on 2013-03-07. The firm is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Company Info
IPO: 2013-03-07
ACASTI PHARMA INC
3009, Boul. De La Concorde East, Suite 102
Laval QUEBEC H7E 2B5 CA
CEO: Jan D'Alvise
Employees: 32
Phone: 14506864555
ACASTI PHARMA INC / ACST FAQ
What does ACST do?
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The company is headquartered in Laval, Quebec. The company went IPO on 2013-03-07. The firm is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Can you provide the latest stock price for ACASTI PHARMA INC?
The current stock price of ACST is 3.37 USD. The price decreased by -0.88% in the last trading session.
What is the dividend status of ACASTI PHARMA INC?
ACST does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACST stock?
ACST has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is ACASTI PHARMA INC (ACST) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACST.
What is ACASTI PHARMA INC worth?
ACASTI PHARMA INC (ACST) has a market capitalization of 34.17M USD. This makes ACST a Nano Cap stock.